Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer Hormonal Estrogen Receptor (HER 2) Negative, Hormone Receptor (HR) Positive.

NCT02853071 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.

NCT NCT02853071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02853071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Estracyt® in Metastatic Breast Cancer Hormonal Estrogen Receptor (HER 2) Negative, Hormone Receptor (HR) Positive.
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2017
Completion date
January 31, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer